• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    Dechra Receives FDA Approval for First U.S. Generic Entrant Antibiotic

    Chelsea Pratt
    Sep. 09, 2016 03:42AM PST
    Life Science Investing News

    Dechra is pleased to announce that it has received approval from the U.S. Food and Drug Administration for a generic antibiotic. The product is expected to be a first generic market entrant in a substantial antibiotic market.

    LONDON, September 9, 2016 /PRNewswire/ —
    Dechra (LON:DPH) is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) for a generic antibiotic.
    The product is expected to be a first generic market entrant in a substantial antibiotic market; it is the first registration Dechra has achieved through Putney’s development pipeline since it acquired the US-based business and clearly demonstrates the capabilities of our specialist pharma team, a key resource to the Group.
    Commenting on the approval Dechra’s Chief Executive Officer, Ian Page said:
    “We are delighted to receive this approval which provides excellent growth opportunity for our US team and underpins our confidence in the strength of the recently acquired Putney business whilst further enhancing Dechra‘s position in the US market.“
    The Group’s Preliminary results for the year ended 30 June 2016 were released on 5 September 2016. The Annual Report is now available on the Group website.
    For more information, please visit: https://www.dechra.com or e-mail: corporate.enquiries@dechra.com .
    SOURCE Dechra Pharmaceuticals PLC

    food and drug administrationfda approvalsgeneric drugsus market
    The Conversation (0)

    Go Deeper

    AI Powered
    Scientist with petri dish.

    Pharma Market Forecast: Top Trends for Pharma in 2025

    Pharmaceutical Investing

    Generic Drugs Lead the FDA's Competition Action Plan

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×